Evidence map›Paper›PMID 25724553›Full record

Observational studySleep & breathing = Schlaf & Atmung2015

IGF-1: a potential biomarker for efficacy of sleep improvement with automatic airway pressure therapy for obstructive sleep apnea?

Vincent Mysliwiec, Jessica Gill, Panagiotis Matsangas, Tristin Baxter, Taura Barr, Bernard J Roth

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Sleep & breathing = Schlaf & Atmung, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Symptoms During CPAP Therapy Are the Major Reason for Contacting the Sleep Unit Between Two Routine Contacts.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2019
    Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Vincent MysliwiecMedical Specialties Clinic, 121st General Hospital, Unit #15281, APO AP, 96205-5281, Seoul, Korea.
Jessica GillNational Institute of Nursing Research, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
Panagiotis MatsangasDepartment of Operations Research, Naval Postgraduate School, 1411 Cunningham Road, Monterey, CA, 93943, USA.
Tristin BaxterDepartment of Pulmonary, Critical Care, Sleep Medicine, Madigan Army Medical Center, 9040A Fitzsimmons Avenue, Tacoma, WA, 98431, USA.
Taura BarrWest Virginia University, 1 Medical Center Drive, Morgantown, WV, 26506, USA.
Bernard J RothDepartment of Pulmonary, Critical Care, Sleep Medicine, Madigan Army Medical Center, 9040A Fitzsimmons Avenue, Tacoma, WA, 98431, USA. bernard.j.roth.civ@mail.mil.
Madigan Army Medical Center · USHanil General Hospital · KRNational Institute of Nursing Research · USNaval Postgraduate School · USWest Virginia University · US

Funding

Traumatic Brain Injury and Sleep Disorders in Military PersonnelZIANR000027 · NINR · NATIONAL INSTITUTE OF NURSING RESEARCH · PI GILL, JESSICA · 2013 to 2021
$4.8M
6 · The paper itself

Abstract

backgroundPositive airway pressure (PAP) reverses obstructive sleep apnea (OSA)-related hypoxia and restores slow wave sleep (SWS). Insulin-like growth factor 1 (IGF-1) is a neuropeptide that facilitates the repair of neurons from hypoxia and improves sleep regulation. IGF-1 concentrations are lower in OSA, and likely increase following PAP treatment; however, this relationship has not yet been determined in a younger cohort of OSA patients.

methodsThis was a prospective, observational pilot study of 58 young men, who were diagnosed with OSA and provided PAP as an intervention. Adherence to PAP treatment over 3 months was objectively measured, as well as changes in the apnea-hypopnea index (AHI). Serum concentrations of IGF-1and C-reactive protein (CRP) were measured and correlated with PAP adherence.

resultsIGF-1 concentrations at baseline were similar between PAP adherent 55.5 ± 34.4 ng/ml and PAP nonadherent participants 61.2 ± 27.1 ng/ml (p = 0.4), with the overall mean IGF-1 concentration of 59.0 ± 29.9 ng/ml. At follow-up, adherent participants had concentrations of IGF-1 that were significantly higher 128 ± 59.5 ng/ml compared to nonadherent participants 86.0 ± 47.4 ng/ml (p < 0.01). Increases in IGF-1 concentrations were significantly associated with reductions in AHI (Spearman's rho = -0.409, p = 0.015). Conversely, CRP concentrations did not differ between baseline and follow-up measurements in either group.

conclusionsAdherence to PAP treatment leads to significant increases in IGF-1 concentrations in young men with OSA. While an objective measure of adherence exists, PAP usage does not allow for measure of sleep improvement. IGF-1 may serve as a potential biomarker for the efficacy of PAP therapy on improved sleep.

Indexed as

AdultAge FactorsBiomarkersCohort StudiesHumansInsulin-Like Growth Factor IIraq War, 2003-2011MaleMilitary PersonnelPolysomnographyPositive-Pressure RespirationProspective StudiesSleep Apnea, ObstructiveTreatment OutcomeYoung AdultBiomarkersInsulin-Like Growth Factor IAdherenceInsulin-like growth factor (IGF-1)Obstructive sleep apneaPositive airway pressure (PAP)

Identifiers

PMID25724553
OpenAlexW2048726143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.